BAFIERTAM® (monomethyl fumarate) delayed-release capsules
95 mg
What is BAFIERTAM?
BAFIERTAM is a unique agent in the fumarates class of disease modifying therapies (DMTs), requiring no dietary restrictions and no metabolic conversion.
It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.1
At Cycle, we know that life-changing treatments need life-improving support to match. That’s why we created Cycle Vita™, delivering individualized product support every step of the way with BAFIERTAM.

Support available to you with BAFIERTAM
Start your BAFIERTAM enrollment here
Download and print the enrollment form, share it with your doctor and discuss why you think BAFIERTAM may be suited to your needs.
The first steps
Your Cycle Vita team will quickly get to work with your insurance provider to help you understand your coverage.
We will coordinate seamlessly between different parties, such as insurance companies, doctors, and pharmacists to help you with your Prior Authorization and document requirements.
We will route your BAFIERTAM therapy to the appropriate specialty pharmacy and follow-up to ensure swift shipment of your medication.
Additional assistance, when required, thoughout your journey
If you have commercial insurance, you may be eligible for the Cycle Vita Co-Pay Assistance Program. Commercially insured eligible patients may pay as little as $0. Please contact us to find out more about this and other programs that may be available to you (such as the Bridge Program).
A free supply of BAFIERTAM is available while we secure appropriate Benefit Verification and assist with Prior Authorization activities, as necessary. It may also be requested if you experience a temporary disruption in therapy due to insurance coverage. Bridge duration is driven by insurance coverage and the active collaboration of your clinic.
Our Clinical Support team can provide you with training to help you keep on top of your medication schedule.
Translation services are available on request.
In some cases, an appeal may be needed. Where this is the case, our experienced team will work with your insurer and doctor to understand the requirements and help you with any BAFIERTAM reimbursement gaps.
If you agree, our proactive team will remind your doctor when your BAFIERTAM prescription needs to be renewed, in a timely manner, to ensure an uninterrupted supply of your therapy.
What is multiple sclerosis (MS)?
The exact cause of MS is unknown. Scientists believe it is triggered by several different factors and there is ongoing research to identify the exact cause.2
No two MS patients are the same, and symptoms vary from person to person.3 Some of the main symptoms include problems with vision, fatigue, numbness, pain and bowel or bladder problems.3 Not everyone will experience all of these symptoms.
Diagnosis can be life altering and incredibly emotional for you and your family. There’s a lot to take in and think about, and every patient with MS has a different experience. At Cycle Vita, we are here to support you, for life.
Resources
Footnote
*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.
BAFIERTAM® is a registered trademark of Banner Life Sciences, LLC, a Cycle Pharmaceuticals company.
References
- BAFIERTAM. Prescribing Information. Banner Life Sciences LLC.
- National Multiple Sclerosis Society (2024) What Causes MS? Available at: https://www.nationalmssociety.org/understanding-ms/what-is-ms/what-causes-ms [Accessed: March 6 2025].
- National Multiple Sclerosis Society (2024) Multiple Sclerosis Symptoms. Available at: https://www.nationalmssociety.org/understanding-ms/what-is-ms/ms-symptoms [Accessed: March 6 2025].
